4,901 trials
Healthy
Primary: Part A - Fraction Excreted in Urine and Faeces as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe0-tz) — 1.30…
Healthy
Primary: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to 72h (AUC0-72h) — 13448.03; 13463.07 hours*nanomole/Liter (h·nmol/L)…
Influenza
Primary: Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the…
Healthy
Primary: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 59457.92; 46951.21…
Aging
Primary: Walking Speed Change From Baseline — 0.033; 0.041 meters per second
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib — 22380; 51570; 21070…
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib — 26160; 28400; 7973…
Healthy
Primary: Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C — 3.4; 4.4; 6.4…
Oncology
Primary: Safety and Tolerability of SUPLEXA in Subjects With Malignant Solid Tumour and Haematologic Malignancies. — 25; 3; 2 Participants
Healthy
Primary: Part I: Percentage of Subjects With Drug-related Adverse Events — 16.7; 16.7; 0.0; 0.0 Percentage of participants
Chronic Hepatitis D Infection
Primary: Pharmacokinetic (PK) Parameter for Bulevirtide (BLV): AUCtau — 94.6; 112; 1880; 1810 hours(h)*nanograms per milliliter(ng/mL)
Healthy · Renal Insufficiency
Primary: Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib in Plasma — 19770…
Head and Neck Cancer
Primary: Change in Immune-based Biomarker Expression at Baseline and 2 Months — 0; 1; 2 Participants — p=<0.036
Advanced Solid Tumor
Primary: Dose-normalized Maximum Observed Plasma Concentration (Cmax) of Total Lurbinectedin: Alone and in Combination With Bosentan. — 20.71; 21.39 μg/L/mg
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin — 8.92; 15.2 nanogram per millilitre (ng/mL)